Skip to main content

Table 3 Data from 46 adjuvant radiotherapies from 43 patients

From: Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer

Variables Value
Age at adjuvant radiotherapy (years)  
 Mean/SD/median/range 64.8/5.81/65.3/75 - 54
Time from salvage lymph node dissection to adjuvant RT (months)  
 Mean/SD/median/range 2.75/1.72/2.20/8.4 - 0.8
Region for adjuvant RT n (%)  
 Pelvic right only 2/46 (4.3%)
 Pelvic left only 5/46 (10.9%)
 Pelvic only (left/right/bilateral) 26/46 (57%)
 Retroperitoneal only 5/46 (11%)
 Pelvic and retroperitoneal 14/46 (30%)
 Retroclavicular and retroperitoneal 1/46 (2%)
 Cases with dose escalation on involved region n (%) 11/46 (24.0%)
Method of adjuvant radiotherapy  
 3D-conformal radiotherapy n (%) 29/46 (63%)
 IMRT n (%) 17/46 (37.0%)
 Concurrent radiation of prostatic fossa n (%) 12/46 (26.1%)
Total dose for radiation of prostatic fossa (Gy)  
 Mean/SD/median/range 69.18/2.38/70.20/45.0 – 72.2
Duration of adjuvant radiotherapy (months)  
 Mean/SD/median/range 1.39/0.35/1.37/2.4 – 1.0
 Dose per fraction (Gy) 1.8, 5x1.8/week
Total dose for pelvic or retroperitoneal RT (Gy)  
 Mean/SD/median/range 49.55/4.16/50.40/45.0 – 59.4
 Number of cases with concurrent AHT at radiotherapy n (%) 2/46 (4.3%)
 Patients with concurrent AHT at latest follow up 27/43 (62.8%)
Comorbidities at latest follow1 up n (%)  
 Cardiovascular disease n (%) 10/38 (26.4%)
 Diabetes mellitus n (%) 3/38 (7.9%)
 Concurrent malignant disease n (%) 3/38 (7.9%)
 Chronic disease/chronic pain n (%) 6/38 (15.9%)
  1. RT = Radiotherapy.
  2. AHT = Antihormonal therapy.
  3. IMRT = Intensity-modulated radiation therapy.
  4. 1Mean 3.2 (SD: 2.8) years after end of radiotherapy.